Edition:
United Kingdom

Prothena Corporation PLC (PRTA.OQ)

PRTA.OQ on NASDAQ Stock Exchange Global Select Market

10.70USD
18 Apr 2019
Change (% chg)

$-0.06 (-0.56%)
Prev Close
$10.76
Open
$10.73
Day's High
$10.85
Day's Low
$10.43
Volume
96,522
Avg. Vol
135,727
52-wk High
$38.76
52-wk Low
$8.66

Latest Key Developments (Source: Significant Developments)

Prothena Reports Results From The Phase 3 VITAL Amyloidosis Study Of NEOD001 In AL Amyloidosis
Thursday, 18 Apr 2019 

April 18 (Reuters) - Prothena Corporation PLC ::PROTHENA REPORTS RESULTS FROM THE PHASE 3 VITAL AMYLOIDOSIS STUDY OF NEOD001 (BIRTAMIMAB) IN AL AMYLOIDOSIS.PROTHENA CORPORATION PLC - RESULTS FROM FINAL ANALYSIS OF COMPOSITE PRIMARY ENDPOINT WERE CONSISTENT WITH FUTILITY ANALYSIS REPORTED IN APRIL 2018.PROTHENA CORPORATION PLC - EXPLORING POTENTIAL BUSINESS DEVELOPMENT OPPORTUNITIES TO ADVANCE NEOD001.PROTHENA CORPORATION PLC - RESULTS FROM POST HOC ANALYSES REVEALED A POTENTIAL SURVIVAL BENEFIT WITH NEOD001.PROTHENA CORPORATION PLC - EXPLORING POTENTIAL BUSINESS DEVELOPMENT OPPORTUNITIES TO ADVANCE NEOD001.PROTHENA CORPORATION PLC - EXPLORING POTENTIAL BUSINESS DEVELOPMENT OPPORTUNITIES THAT COULD RESULT IN FURTHER CLINICAL INVESTIGATION OF NEOD001.PROTHENA CORPORATION PLC - NEOD001 AND CONTROL ARMS HAD SIMILAR FREQUENCIES OF TREATMENT EMERGENT ADVERSE EVENTS AND SERIOUS ADVERSE EVENTS.  Full Article

Prothena Q3 Loss Per Share $0.62
Tuesday, 6 Nov 2018 

Nov 6 (Reuters) - Prothena Corporation PLC ::PROTHENA REPORTS THIRD QUARTER 2018 FINANCIAL RESULTS AND PROVIDES RESEARCH AND DEVELOPMENT UPDATE.Q3 LOSS PER SHARE $0.62.Q3 EARNINGS PER SHARE VIEW $-0.98 -- THOMSON REUTERS I/B/E/S.QUARTER-END CASH AND RESTRICTED CASH POSITION OF $455.6 MILLION.CONTINUES TO EXPECT ITS 2018 NET CASH BURN FROM OPERATING AND INVESTING ACTIVITIES TO BE $40 TO $50 MILLION.PROTHENA - ESTIMATED 2018 NET CASH BURN FROM OPERATING AND INVESTING ACTIVITIES IS PRIMARILY DRIVEN BY AN ESTIMATED NET LOSS OF $170 TO $185 MILLION.  Full Article

Prothena Q3 Loss Per Share $0.62
Tuesday, 6 Nov 2018 

Nov 6 (Reuters) - Prothena Corporation PLC ::PROTHENA REPORTS THIRD QUARTER 2018 FINANCIAL RESULTS AND PROVIDES RESEARCH AND DEVELOPMENT UPDATE.Q3 LOSS PER SHARE $0.62.Q3 EARNINGS PER SHARE VIEW $-0.98 -- THOMSON REUTERS I/B/E/S.QTRLY TOTAL REVENUE $255,000 VERSUS $219,000.Q3 REVENUE VIEW $802430.00 -- THOMSON REUTERS I/B/E/S.CONTINUES TO EXPECT ITS 2018 NET CASH BURN FROM OPERATING AND INVESTING ACTIVITIES TO BE $40 TO $50 MILLION.  Full Article

Prothena Announces Global Neuroscience Research & Development Collaboration With Celgene
Tuesday, 20 Mar 2018 

March 20 (Reuters) - Prothena Corporation Plc ::PROTHENA ANNOUNCES GLOBAL NEUROSCIENCE RESEARCH & DEVELOPMENT COLLABORATION WITH CELGENE FOR NOVEL THERAPIES FOR PATIENTS WITH NEURODEGENERATIVE DISEASES.PROTHENA CORPORATION - PROTHENA TO RECEIVE A $100 MILLION UPFRONT PAYMENT AND A $50 MILLION EQUITY INVESTMENT BY CELGENE.PROTHENA CORPORATION- COLLABORATION INCLUDES POTENTIAL LICENSE PAYMENTS, MILESTONES, PLUS ADDITIONAL ROYALTIES ON SALES FROM LICENSED PROGRAMS FOR CO.PROTHENA CORPORATION PLC - CELGENE WILL SUBSCRIBE TO ABOUT 1.2 MILLION OF PROTHENA'S ORDINARY SHARES AT $42.57 PER SHARE.  Full Article

Prothena Corp Files For Potential Stock Shelf Offering
Monday, 26 Feb 2018 

Feb 26 (Reuters) - Prothena Corporation Plc ::PROTHENA CORPORATION PLC FILES FOR POTENTIAL STOCK SHELF OFFERING; SIZE NOT DISCLOSED - SEC FILING.  Full Article

Prothena Q4 Loss Per Share $1.24
Wednesday, 14 Feb 2018 

Feb 14 (Reuters) - Prothena Corporation Plc ::PROTHENA REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS, AND PROVIDES FINANCIAL GUIDANCE AND RESEARCH AND DEVELOPMENT UPDATE.Q4 LOSS PER SHARE $1.24.Q4 REVENUE $200,000.AS OF DECEMBER 31, 2017, PROTHENA HAD $421.7 MILLION IN CASH, CASH EQUIVALENTS AND RESTRICTED CASH AND NO DEBT.EXPECTS THE FULL YEAR 2018 NET CASH BURN FROM OPERATING AND INVESTING ACTIVITIES TO BE $175 TO $230 MILLION.Q4 EARNINGS PER SHARE VIEW $-1.48, REVENUE VIEW $237600.00 -- THOMSON REUTERS I/B/E/S.  Full Article

Prothena reports Q3 loss per share $1.37
Tuesday, 7 Nov 2017 

Nov 7 (Reuters) - Prothena Corporation Plc ::Prothena reports third quarter 2017 financial results and provides research and development update.Q3 loss per share $1.37.Q3 revenue $200,000.Q3 revenue view $251,000 -- Thomson Reuters I/B/E/S.Q3 earnings per share view $-1.39 -- Thomson Reuters I/B/E/S.  Full Article

Prothena reports third quarter financial results
Tuesday, 7 Nov 2017 

Nov 7 (Reuters) - Prothena Corporation Plc :Prothena reports third quarter 2017 financial results and provides research and development update.Q3 loss per share $1.37.Q3 revenue $200,000.Q3 revenue view $251,000 -- Thomson Reuters I/B/E/S.Q3 earnings per share view $-1.39 -- Thomson Reuters I/B/E/S.  Full Article

Prothena reports Q2 loss per share $0.46
Tuesday, 8 Aug 2017 

Aug 9 (Reuters) - Prothena Corporation Plc -:Prothena reports second quarter 2017 financial results and provides research and development update.Q2 loss per share $0.46.Q2 revenue $26.8 million.Q2 revenue view $15.1 million -- Thomson Reuters I/B/E/S.Q2 earnings per share view $-0.88 -- Thomson Reuters I/B/E/S.Prothena Corporation Plc - ‍as of june 30, 2017, prothena had $475.8 million in cash, cash equivalents and restricted cash and no debt.​.Prothena Corporation Plc - ‍expects full year 2017 net cash burn from operating and investing activities to be $160 to $170 million​.  Full Article

Prothena Q2 loss per share $0.46
Tuesday, 8 Aug 2017 

Aug 8 (Reuters) - Prothena Corporation Plc :Prothena reports second quarter 2017 financial results and provides research and development update.Q2 loss per share $0.46.Q2 revenue $26.8 million.Q2 revenue view $15.1 million -- Thomson Reuters I/B/E/S.Q2 earnings per share view $-0.88 -- Thomson Reuters I/B/E/S.Prothena Corporation PLC says we expect topline results from phase 1B mad study of PRX003 in patients with psoriasis in october.Prothena Corporation PLC says expect topline results from phase 2b pronto study of neod001 in patients with al amyloidosis in q2 of 2018.  Full Article